Steven R. Gullans Ph.D., Interim President & CEO at Gemphire Therapeutics Inc. (GEMP), bought 71,429 shares at $7.00 ($500K) on 2018-02-08, disclosed to the SEC on 2018-02-12.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| Filing → |
| GEMP | BUY | 2016-08-12 | $5.0M | — | Filing → |
| TTPH | BUY | 2014-05-21 | $231K | — | Filing → |
| TTPH | BUY | 2013-03-27 | $3.5M | — | Filing → |